Somatostatin Side Effects: What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning a medicine, a hormone therapy or a clinical trial. It summarises what published papers reported and does not describe how any substance should be used.

What the term covers in the published safety literature

Somatostatin is an endogenous inhibitory hormone that signals through a family of somatostatin receptor subtypes and restrains the release of growth hormone and several pancreatic and gastrointestinal hormones. In the clinical literature, however, the word "somatostatin" is attached to at least four quite different research objects, and the adverse-event record differs for each of them:

• Native somatostatin given by intravenous infusion in hospital settings, where the exposure is short and supervised.
• Injected somatostatin receptor ligands (SRLs) — long-acting peptide analogues used chronically, most extensively in acromegaly and neuroendocrine tumour care.
• Oral nonpeptide receptor agonists developed as alternatives to injections and evaluated in healthy-volunteer and switch studies.
• Radiolabelled somatostatin analogues used as peptide receptor radionuclide therapy (PRRT), where the relevant toxicity is largely radiation toxicity rather than receptor pharmacology.

Because the molecule, the route, the duration and the accompanying procedures differ across these categories, tolerability findings reported in one category cannot be read across to another. The sections below keep them separate.

Injected Somatostatin Receptor Ligands: What Studies Report

Chronic injected analogues have the longest clinical history. A 2004 review of acromegaly treatment placed somatostatin analogues among the principal medical options alongside surgery, radiotherapy and other pharmacological approaches, and discussed how treatment choice was framed in that era (PMID 15539805). That review is a narrative overview rather than a safety dataset, and it does not supply incidence figures that could be quoted here.

Injection-related experience

One of the more specific tolerability questions in this category concerns the injections themselves rather than systemic pharmacology. A 2022 comparison published in Revista da Associação Médica Brasileira examined somatostatin analogue injections and reported comparative findings on the injection experience, including injection-related discomfort as perceived by patients (PMID 35649076). Researchers in that comparison treated the administration burden as a measurable outcome in its own right, which is one reason later programmes tested oral alternatives.

What this evidence set does not quantify

Clinicians commonly discuss gallbladder changes, altered glucose handling and gastrointestinal complaints in connection with long-term analogue therapy. Within the verified papers assembled for this page, no study provides itemised incidence rates for those specific events, so no percentages are stated here. That is an absence of data in this particular evidence set, not evidence that such events do not occur; readers comparing sources should expect dedicated long-term registries and product labelling to carry that detail.

Oral Nonpeptide SST2 Agonist Trials: What Studies Report

A separate strand of research asked whether a small-molecule agonist at the SST2 receptor could reproduce the biochemical effects of injected peptides. In a study of healthy volunteers, researchers reported that paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppressed growth hormone and IGF-1 (PMID 35000098). That early-phase work established pharmacodynamic activity in people without acromegaly and, being a first-in-human style investigation, was designed around safety and tolerability monitoring rather than clinical outcomes.

Two later reports examined what happened when patients already controlled on injected ligands were moved to the oral agent. The ACROBAT Edge study assessed the safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly (PMID 36353760). A subsequent 2024 report in The Journal of Clinical Endocrinology and Metabolism described acromegaly disease control being maintained after switching from injected somatostatin receptor ligands to oral paltusotine (PMID 38828555). Both were conducted in defined patient populations under trial monitoring; neither is a long-duration post-marketing surveillance dataset, and the switch design means their tolerability observations describe patients who had already demonstrated they could tolerate receptor-directed therapy.

Radiolabelled Somatostatin Analogues (PRRT): What Studies Report

The most granular adverse-event documentation in this evidence set comes from radiolabelled analogues, where the peptide serves as a delivery vehicle for a therapeutic radionuclide.

Long-term haematological findings

A long-term analysis of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumours reported on efficacy, survival and safety together, and the study documented subacute haematological toxicity as well as cases of myelodysplastic syndrome and acute leukaemia arising during long-term follow-up (PMID 28428192). Those events are the reason haematological surveillance is a structural part of how the therapy is studied. Narrative reviews of the same agent for gastroenteropancreatic neuroendocrine tumours similarly discuss the balance between antitumour activity and toxicity when summarising the trial record (PMID 31652074), and a 2022 review of peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTA-TATE covered the same therapeutic framework from a nuclear-medicine perspective (PMID 34920969).

Organs at risk and dosimetry

Radiation-based therapy is governed by absorbed dose to normal tissue rather than by milligram quantities of peptide. The EANM dosimetry committee published recommendations for dosimetry of ¹⁷⁷Lu-labelled somatostatin-receptor- and PSMA-targeting ligands, setting out how absorbed doses to organs at risk should be measured and reported so that toxicity can be interpreted consistently across centres (PMID 35284969). Broader overviews of internal radiation therapy place receptor-targeted radionuclide treatment within the wider family of internally administered radiation approaches and their associated safety considerations (PMID 32594411). These documents are methodological: they describe how risk is quantified, not how an individual should be treated.

An important reading point is that the toxicity profile in this section belongs to the radionuclide and the delivery procedure. It does not describe what unlabelled somatostatin or an unlabelled analogue would be expected to do.

Native Somatostatin Infusion in Hospital Settings: What Studies Report

Native somatostatin has been investigated as a short-course infusion for specific complications. One report described somatostatin therapy in patients with massive ascites after liver transplantation (PMID 30598518). The study was conducted in a hospitalised transplant population under continuous monitoring, which is the opposite of unsupervised exposure; its observations therefore speak to a narrow clinical scenario and a short treatment window, and the verified set contains no comparable long-duration study of native somatostatin in healthy people.

Receptor subtype selectivity and why profiles diverge

Part of the reason different somatostatin-directed agents carry different tolerability patterns is which receptor subtypes they engage. A 2025 structural study reported the binding modes of lanreotide and pasireotide with somatostatin receptor 1, providing molecular detail on how peptide analogues engage that subtype (PMID 40487642). Work of this kind is mechanistic and structural; it contains no human adverse-event data and cannot be used to predict clinical tolerability. By contrast, the paltusotine programme was explicitly framed around SST2 selectivity in an oral molecule (PMID 35000098), illustrating how receptor targeting is treated as a design variable rather than an afterthought.

How the evidence compares across settings

Where this literature is silent

Three absences are worth stating plainly. First, none of the verified papers studied native somatostatin or its analogues in healthy adults for non-clinical purposes, so there is no adverse-event dataset in this set describing such use. Second, the haematological events documented for radiolabelled therapy (PMID 28428192) arise in the context of a delivered radiation dose and are not transferable to unlabelled peptides. Third, the oral-agonist switch trials reported maintained disease control in already-treated acromegaly patients (PMID 38828555), which is a different question from first-line long-term safety in an untreated population.

Limitations of reading across these studies

1. Population mismatch. Acromegaly, neuroendocrine tumour and post-transplant populations differ from one another and from healthy volunteers, and baseline comorbidity shapes which adverse events are recorded.
2. Design mismatch. Reviews and dosimetry recommendations (PMID 35284969) describe methods and syntheses rather than generating new incidence data.
3. Exposure mismatch. A short supervised infusion (PMID 30598518) and years of depot injections are not comparable exposures.
4. Reporting conventions. Trials record treatment-emergent adverse events by protocol definitions, while narrative reviews summarise them selectively.

Continuing with the fundamentals

This page is limited to what published studies report about tolerability and adverse events. The PeptideU somatostatin course at /learn/somatostatin/ covers the underlying biology — receptor subtypes, hormonal feedback and how analogues were developed — and is structured as teaching material rather than a safety review, so the two resources are intended to complement rather than repeat one another.

References

• Treatment of acromegaly (Hormone Research, 2004)
• Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors (Clinical Cancer Research, 2017)
• Somatostatin Therapy in Patients with Massive Ascites After Liver Transplantation (Annals of Transplantation, 2019)
• 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors (Expert Review of Gastroenterology & Hepatology, 2019)
• Internal Radiation Therapy (Recent Results in Cancer Research, 2020)
• Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE (Revista Espanola de Medicina Nuclear e Imagen Molecular, 2022)
• Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers (Pituitary, 2022)
• EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands (European Journal of Nuclear Medicine and Molecular Imaging, 2022)
• Comparison between somatostatin analog injections (Revista da Associacao Medica Brasileira, 2022)
• ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly (The Journal of Clinical Endocrinology and Metabolism, 2023)
• Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine (The Journal of Clinical Endocrinology and Metabolism, 2024)
• Structural insights into the binding modes of lanreotide and pasireotide with somatostatin receptor 1 (Acta Pharmaceutica Sinica B, 2025)